CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
0.2104
-0.0096 (-4.36%)
Apr 2, 2025, 4:00 PM EST - Market closed
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
16.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
CVM News
- 9 days ago - CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Business Wire
- 15 days ago - CEL-SCI Announces Closing of $2.5 Million Offering - Business Wire
- 16 days ago - CEL-SCI Announces Pricing of $2.5 Million Offering - Business Wire
- 16 days ago - CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Business Wire
- 19 days ago - Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression - Business Wire
- 5 weeks ago - CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Business Wire
- 6 weeks ago - CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - Business Wire
- 2 months ago - CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Business Wire